Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603203, India.
Department of Pathology, Wayne State University School of Medicine, Detroit, MI, 48201, USA.
Cell Oncol (Dordr). 2018 Jun;41(3):223-252. doi: 10.1007/s13402-018-0378-4. Epub 2018 Apr 17.
Recent advances in cancer biology have highlighted the relevance of exosomes and nanovesicles as carriers of genetic and biological messages between cancer cells and their immediate and/or distant environments. It has been found that these molecular cues may play significant roles in cancer progression and metastasis. Cancer cells secrete exosomes containing diverse molecules that can be transferred to recipient cells and/or vice versa to induce a plethora of biological processes, including angiogenesis, metastasis formation, therapeutic resistance, epithelial-mesenchymal transition and epigenetic/stemness (re)programming. While exosomes interact with cells within the tumour microenvironment to promote tumour growth, these vesicles can also facilitate the process of distant metastasis by mediating the formation of pre-metastatic niches. Next to their tumour promoting effects, exosomes have been found to serve as potential tools for cancer diagnosis and therapy. The ease of isolating exosomes and their content from different body fluids has led to the identification of diagnostic and prognostic biomarker signatures, as well as to predictive biomarker signatures for therapeutic responses. Exosomes can also be used as cargos to deliver therapeutic anti-cancer drugs, and they can be engineered to serve as vaccines for immunotherapy. Additionally, it has been found that inhibition of exosome secretion, and thus the transfer of oncogenic molecules, holds promise for inhibiting tumour growth. Here we provide recent information on the diverse roles of exosomes in various cellular and systemic processes governing cancer progression, and discuss novel strategies to halt this progression using exosome-based targeted therapies and methods to inhibit exosome secretion and the transfer of pro-tumorigenic molecules.
This review highlights the important role of exosomes in cancer progression and its implications for (non-invasive) diagnostics and the development of novel therapeutic strategies, as well as its current and future applications in clinical trials.
近年来癌症生物学的进展强调了外泌体和纳米囊泡作为癌细胞与其周围和/或远处环境之间遗传和生物学信息载体的相关性。已经发现这些分子线索可能在癌症进展和转移中发挥重要作用。癌细胞分泌含有多种分子的外泌体,这些分子可以转移到受体细胞中,反之亦然,从而诱导多种生物学过程,包括血管生成、转移形成、治疗抵抗、上皮-间充质转化和表观遗传/干性(重新)编程。虽然外泌体与肿瘤微环境中的细胞相互作用以促进肿瘤生长,但这些囊泡还可以通过介导前转移龛的形成来促进远处转移的过程。除了具有促进肿瘤的作用外,外泌体还被发现可作为癌症诊断和治疗的潜在工具。从不同体液中分离外泌体及其内容物的简便性导致了诊断和预后生物标志物特征的鉴定,以及治疗反应的预测生物标志物特征的鉴定。外泌体还可以用作运载药物的载体来输送治疗性抗癌药物,并且可以对其进行工程改造以作为免疫疗法的疫苗。此外,已经发现抑制外泌体的分泌,从而抑制致癌分子的转移,有望抑制肿瘤生长。本文提供了关于外泌体在各种细胞和系统过程中在控制癌症进展中的不同作用的最新信息,并讨论了使用基于外泌体的靶向治疗和抑制外泌体分泌和促进肿瘤形成分子转移的方法来阻止这一进展的新策略。
本综述强调了外泌体在癌症进展中的重要作用及其对(非侵入性)诊断和新治疗策略的发展的影响,以及其在临床试验中的当前和未来应用。